Related Experiment Video
Updated: Aug 21, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Anemia during treatment of hepatitis C in HIV-infected patients
1Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelpha, Pennsylvania, USA.
Abstract:
Anemia is a significant adverse effect of current hepatitis C treatment and may be a particular problem for HIV-infected patients, in whom there is a high prevalence of disease- or drug-related anemia at baseline. Hepatitis C treatment-induced anemia in HIV-HCV-coinfected patients can lead to ribavirin dose reduction or premature discontinuation of hepatitis C therapy, limiting sustained virologic response rates. Mean decreases in hemoglobin levels during hepatitis C treatment appear to be less in HIV-HCV-coinfected patients than in HCV-monoinfected patients, but any decrease in hemoglobin level may be more of a problem for coinfected patients. Thus, close monitoring of the hemoglobin level and appropriate management of the anemia that may develop in HIV-infected patients during hepatitis C therapy is essential.
Related Concept Videos
Hepatitis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Hemodialysis II: Procedure and Complications
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Retrovirus Life Cycles
